Company / Operating Income
Xilio Therapeutics, Inc. Operating Income History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$60.6M
FY2025
5-year range
-$79.1M / -$60.6M
FY2024-FY2025
Trend
+23.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
-$61M in FY2025.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 23.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score -0.71 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$60.6M | +23.4% |
| FY2024 | -$79.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026